Document is current
Any future updates will be listed below
-
Authors
Lam, W. K. Jacky https://orcid.org/0000-0001-8922-5609
Gai, Wanxia https://orcid.org/0000-0001-9097-9141
Bai, Jinyue
Tam, Tommy H. C.
Cheung, Wai Fung https://orcid.org/0000-0001-5383-4509
Ji, Lu
Tse, Irene O. L.
Tsang, Amy F. C.
Li, Maggie Z. J.
Jiang, Peiyong https://orcid.org/0000-0003-4523-3476
Law, Man Fai
Wong, Raymond S. M.
Chan, K. C. Allen
Lo, Y. M. Dennis https://orcid.org/0000-0001-8746-0293
-
Funding
Funding for this research was provided by:
Innovation and Technology Commission (InnoHK Innitiative, InnoHK Initiative, InnoHK Initiative, InnoHK Initiative, InnoHK Initiative, InnoHK Initiative, InnoHK Initiative, InnoHK Initiative, InnoHK Initiative, InnoHK Initiative, InnoHK Initiative)
Li Ka Shing Foundation (NA)
- License Information
-
More Information
Article History
Received: 8 April 2023
Accepted: 11 July 2024
First Online: 5 August 2024
Competing interests
: K.C.A.C. and Y.M.D.L. hold equities in DRA, Take2, Insighta and Grail/Illumina. K.C.A.C. and Y.M.D.L. were consultants to Grail/Illumina. Y.M.D.L. is a scientific co-founder of and previously served on the scientific advisory board of Grail. W.K.J.L. and P.J. hold equities in Grail/Illumina. P.J. is a consultant to Take2. P.J. is a Director of DRA and KingMed Future. W.K.J.L. is a director of DRA.
